Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment
- PMID: 23647578
- DOI: 10.1111/aos.12153
Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment
Abstract
Purpose: To evaluate macular morphology and function in diabetic macular edema (DME) over the course of intravitreal anti-vascular endothelial growth factor (VEGF) treatment with Ranibizumab.
Methods: A consecutive series of 39 study eyes with centre-involving DME were included in this study. In all subjects, best-corrected visual acuity (BCVA) according ETDRS protocol, fluorescein angiography (FA), microperimetric macular sensitivity (MP) and Spectral Domain optical coherence tomography (SD-OCT) cross-sectional scans were obtained before treatment and after 3 monthly applied intravitreal Ranibizumab injections. Six different morphological qualities [IS/OS layer integrity, outer nuclear layer (ONL) cysts, ONL cyst size, inner nuclear layer (INL) cysts, blocking phenomenon and subretinal fluid] were graded of each cross-sectional OCT scan before and over the course of treatment by two experienced graders. Correlation analyses between functional and morphological parameters were obtained.
Results: Mean BCVA increased from 26 ± 14 to 33 ± 13 letters after 3 consecutive monthly applied Ranibizumab injections (p < 0.001). Central retinal thickness (CRT) decreased from 504 ± 144 to 387 ± 122 μm (p < 0.001). Over the course of treatment, IS/OS continuity improved (index: 0.56 ± 0.52 to 0.43 ± 0.49, Z = -1.415, p = 0.157), ONL cyst prevalence and size decreased significantly (index: 0.61 ± 0.44 to 0.56 ± 0.35, Z = -3.41, p = 0.001 and 1.75 ± 0.88 to 1.17 ± 1.05, Z = -4.02, p < 0.001), INL cyst prevalence decreased (index: 0.35 ± 0.52 to 0.28 ± 0.52, Z = -1.60, p = 0.109), blocking phenomenon did not change significantly (index: 00.12 ± 0.16 to 0.13 ± 0.15, Z = -0.45, p = 0.656) and subretinal fluid almost disappeared (index: 0.10 ± 0.24 vs. 0.00 ± 0.01, Z = -2.56, p = 0.011). Correlation analyses revealed highest significant correlations between ONL cyst prevalence and their size and CRT as well as BCVA and MP before treatment and over the course of treatment.
Conclusions: ONL cysts and their size as morphological parameters correlate with retinal function measured with BCVA and microperimetry before and over the course of anti-VEGF therapy with Ranibizumab in patients with DME.
Keywords: Ranibizumab; anti-vascular endothelial growth factor; diabetic macular edema; diabetic retinopathy; imaging; microperimetry; optical coherence tomography.
© 2013 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
Similar articles
-
Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year.Ophthalmology. 2009 Dec;116(12):2415-21. doi: 10.1016/j.ophtha.2009.05.001. Epub 2009 Sep 10. Ophthalmology. 2009. PMID: 19744723
-
Degree of decrease in central retinal thickness predicts visual acuity response to intravitreal ranibizumab in diabetic macular edema.Ophthalmologica. 2014;231(1):16-22. doi: 10.1159/000355487. Epub 2013 Nov 22. Ophthalmologica. 2014. PMID: 24280908
-
Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.Retina. 2006 Nov-Dec;26(9):999-1005. doi: 10.1097/01.iae.0000247165.38655.bf. Retina. 2006. PMID: 17151486 Clinical Trial.
-
Diabetic macular edema.Ophthalmologica. 2012;227 Suppl 1:21-9. doi: 10.1159/000337156. Epub 2012 Apr 24. Ophthalmologica. 2012. PMID: 22517122 Review.
-
[Intravitreal ranibizumab in diabetic macular edema].Klin Oczna. 2010;112(10-12):333-6. Klin Oczna. 2010. PMID: 21473086 Review. Polish.
Cited by
-
En face image-based classification of diabetic macular edema using swept source optical coherence tomography.Sci Rep. 2021 Apr 7;11(1):7665. doi: 10.1038/s41598-021-87440-3. Sci Rep. 2021. PMID: 33828222 Free PMC article.
-
Current Treatments for Diabetic Macular Edema.Int J Mol Sci. 2023 May 31;24(11):9591. doi: 10.3390/ijms24119591. Int J Mol Sci. 2023. PMID: 37298544 Free PMC article. Review.
-
Optical Coherence Tomography Biomarkers Predict the Long-Term Restorative Effect of Early Anti-VEGF Treatment on Diabetic Macular Edema.Life (Basel). 2025 Feb 11;15(2):269. doi: 10.3390/life15020269. Life (Basel). 2025. PMID: 40003678 Free PMC article.
-
Ranibizumab with luseogliflozin in type 2 diabetes with diabetic macular oedema: A randomised clinical trial.Diabetes Obes Metab. 2025 May;27(5):2473-2484. doi: 10.1111/dom.16244. Epub 2025 Feb 11. Diabetes Obes Metab. 2025. PMID: 39935097 Free PMC article. Clinical Trial.
-
Three-dimensional analysis of morphologic changes and visual outcomes in diabetic macular edema.Jpn J Ophthalmol. 2019 May;63(3):234-242. doi: 10.1007/s10384-019-00657-8. Epub 2019 Feb 19. Jpn J Ophthalmol. 2019. PMID: 30783942
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials